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Abstract
Background: Cardiovascular disease is the leading cause of death worldwide. Outcomes of
patients with ST-segment–elevation myocardial infarction (STEMI) have improved through
widespread implementation of systems-of-care, yet sex disparities continue to be reported.
A comprehensive, global study of sex disparities in contemporary STEMI care and
outcomes has not been undertaken.
Objective: To examine whether sex differences in STEMI management and mortality
outcomes persist worldwide and by geographic region.
Methods: A systematic PubMed literature search was performed using search terms “sex”
or “gender” and “STEMI” for studies in English from 2000 to present reporting sex-based
STEMI mortality. Articles with primary data on sex-based STEMI mortality were included.
Data collected prior to 2000, sub-categorized data, and studies with less than 50 women
were excluded. Meta-analyses were conducted using random effects models and are
reported overall and by geographic region. Heterogeneity was assessed via Cochran’s Q
statistic. Sex differences were evaluated in baseline characteristics, door-to-balloon times,
and mortality (in-hospital, 30-day, 6 months, and 1 year).
Main Outcome and Measure: The primary outcome is in-hospital to 12-month mortality.
Secondary outcome is Door-to-Balloon/Door-to-Reperfusion time.
Results: 613 published manuscripts were reviewed and ultimately 75 studies included in
the meta-analysis, representing 29 countries in 6 geographic regions and 731,990 patients
(32% female). Women were older and had more diabetes and hypertension. Overall,
unadjusted in-hospital mortality was 2-fold higher in women compared to men (2.09 OR,
95%CI 1.91-2.08; p<0.0001), with excess mortality in all regions and time-points.
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Adjusting for age alone did not alter the mortality discrepancy. After adjustment for
hypertension and diabetes the difference in sex-based mortality was no longer significant.
Additionally, reperfusion therapy was less common in women, door-to-reperfusion time
was longer in all countries with a mean delay of 5.3 minutes (p<0.0001).
Conclusions: This study demonstrates concerning global sex disparities in risk factors, time
to treatment, STEMI care and a doubling of unadjusted mortality in women. Adjustments
for comorbidities suggest that modifiable risk factors, rather than difference in reperfusion
therapy, account primarily for the difference in mortality. This highlights the need for a
global call-to-action to elucidate critical factors and barriers to preventive care to reduce
the observed sex gap in STEMI outcomes worldwide.
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Introduction
Background
Acute myocardial infarction (AMI) is the leading cause of death worldwide1-3.
Although historically perceived as predominantly an ailment of men, it is the principal
cause of death for women, both in the United States and globally1,4. ST-segment Elevation
Myocardial Infarction (STEMI), its deadliest form5,6, requires emergent reperfusion and
revascularization with primary percutaneous coronary intervention (PPCI) to reduce the
high rates of morbidity and mortality7-9. “Time is myocardium”, the old cardiology maxim
goes, asserting that successful intervention is dependent on minimizing time of ischemia.
That is, the time from symptom onset to the restoration of coronary blood flow. Current
guidelines have set this optimal golden window, now known as door-to-balloon (D2B)
time, at less than 90 minutes10-12.
Over the past decade, organizations such as Mission Lifeline13-15 (2007, American
Heart Association) and Stent-for-Life16,17 (2009, European Society of Cardiology) were
established to meet these goals on a national and international level. These initiatives not
only tackled the root causes behind system-barriers to timely reperfusion, but also
revolutionized the approach to STEMI care in the U.S. and Europe. This involved
implementing essential core measures, generating robust national data registries,
instituting standardized protocols to decrease reperfusion times, and establishing efficient
and reliable networks of care10,11,18-20.
These US and EU based initiatives have resulted in dramatic improvements in
STEMI mortality rates21-23, but at the same time accentuated the gap in STEMI mortality in
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other regions of the world – many of which face an increasing AMI burden20,24. It also
revealed previously under-recognized discrepancies in treatment times associated with
sex, age, race, and socioeconomic status25-28. Underprivileged and traditionally
marginalized social groups, including women, combined with insufficient regional
resources and infrastructure, historically has lead to a pervasive sex gap in STEMI care and
outcomes. Whether this sex gap persists with the current widespread adoption of systems
of care, remains unknown.
Epidemiology
For decades, coronary heart disease (CHD) has been a leading cause of morbidity
and mortality for women worldwide. Moreover, since the 1980’s, the annual mortality rate
of AMI in the US has been higher for women than for men. Today, despite a decade of
considerable improvement in systems of care and reduction in mortality rates in developed
countries, AMI remains the number one killer of women both in the US, and globally1.
Furthermore, the lifetime risk for CHD at age 70 in American women is a staggering 1 in 3,
fivefold higher than the infamous 1 in 8 statistic often cited for breast cancer29. Annually,
6.6 million women in the US suffer from CHD. Of these, 2.7 million had an AMI, over 50,000
died as a result of their MI, and approximately 262,000 were admitted for ACS (AMI and
unstable angina)1. These statistics are, of course, much worse in lower-income countries20,24.
Still, despite mounting evidence throughout the years, the risk of cardiovascular
disease (CVD) in general, and CHD in particular, is frequently underestimated in women. It
has been suggested that at the core of this misperception is an anachronistic fallacy that
females, particularly at younger ages, are ‘protected’ from CVD, and as an extension CHD.
Debunking this misconception, are ample data, most recently from the National Health and
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Nutrition Examination Surveys that demonstrate that over the past two decades the
prevalence of myocardial infarctions has increased in premenopausal women of ages 34-54
years30-32.
Globally, similar trends are slowly starting to emerge33. Research from various
developing regions of the world shows higher comorbidity burden (mainly, DM and
hypertension) in women as compared to men, as well as an accompanying higher CHD and
STEMI mortality rates20,24. This is seen in research from South Asia (e.g., India, Pakistan, Sri
Lanka)34,35, China36 and Taiwan37, the Middle East (e.g., Bahrain, Kuwait, Qatar and
Yemen)38, and Latin America (e.g., Brazil and Mexico)39.

A Question of Representation
As already established, CVD and CHD are equal opportunity killers. Nevertheless,
when it comes to cardiovascular research, particularly clinical trials, women have
historically been, and continue to be, underrepresented40-42. Perhaps the most absurd
example is that of the Coronary Drug Project43. This first large clinical trial, launched by the
National Heart, Lung, and Blood Institute, included a randomized controlled trial that, in
light of Framingham data demonstrating a 10-year lag in female cardiovascular mortality
relative to men44, evaluated the effects of estrogen for the secondary prevention of CHD
exclusively in men post-myocardial infarction. Suffice it to say that, although the study was
stopped early due to higher mortality in the treatment arm, the administration of
supplemental estrogen to postmenopausal women continued for years, solely based on
observational data in women45,46. No words describe this historical folly more aptly than
the words of cardiologist Dr. Wenger of Emory: “For many years, the medical community
has viewed women’s health with a bikini approach, focusing essentially on the breast and
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reproductive system. The rest of the woman was virtually ignored in considerations of
women’s health”47.
Surely such grave historical imbalances have been sufficiently addressed, one might
conclude. Unfortunately, the historical, routine underrepresentation of women in
cardiovascular clinical trials and registries is alive and well. Two relatively recent and
major studies from the Institute of Medicine48,49 and one from the European Heart Health
Strategy50, emphasize that although significant strides have been made in medical care and
outcomes of women with CHD, aside from reproductive care, medical research had mostly
neglected women’s health needs. Female subjects rarely represent more than 20-30% of
subjects in clinical trials and ~40% of most patient registries41,42,51. As a result, an accurate
epidemiologic snapshot of regional and global data on CHD and their dissection by
geographic region, clinicopathologic subtype, temporal trends, and especially biosocial
parameters (e.g., sex and gender) remains lacking and inaccurate52. This is further
bolstered by that fact that robust population-based studies do not exist in large swaths of
the developing world, where registries and clinical trials are much less common in the first
place.
Consequently, significant knowledge gaps undermine our ability to accurately
assess whether our treatment and prevention efforts have culminated in significant local
and global changes in the incidence and prevalence of CHD in women. A testament to this
challenge is the discrepancy between studies suggesting a temporal stagnation or increase
in MI incidence (e.g., Framingham Heart Study and ARIC), and those suggesting a temporal
decrease (e.g., Minnesota Heart Survey and Rochester Epidemiology Project)52.
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Despite this gloomy backdrop, the progress that has been made by research focused
on women’s health and CHD over the past decade has improved our understanding of the
unique female pathophysiology, sex differences in clinical presentation, and contribution of
biopsychosocial factors.
Biosocial Trends: The Influence of Age and Race
First presentation of MI in women, particularly STEMI, occurs at an older average
age of 71.8 years as compared to 65 years of age in men31. This “delay” is hypothesized to
be the result of the protective effect of estrogen on the vascular endothelium53. In the last
decade, the annual death rate for both men and women older than 65 years of age has
fallen dramatically, partially reflecting the large reduction in STEMI incidence and
mortality54.
CHD in young women (under age 55) is rare. Annually, in the United States, ~30,000
women under the age of 55 are admitted for AMI55. However, compared to men less than
65 years of age, current data indicates that women of the same age group have almost 2fold higher readmission rates after STEMI56. While CHD death rates fell dramatically among
all US women between 2001-2010, when stratifying by age for the 35-54 year old group,
this decline is absent or in some cases turns to an increase57. Additionally, there exist
concerning evidence that young women in the US have a higher risk of death after AMI,
even when adjusting for other parameters58,59. To date, STEMI-specific data on mortality in
young women is deficient.
Moreover, stratification of American women with AMI by race and ethnicity, unveils
substantial differences in prevalence, presentation, medical care, and outcome. First, black
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women have the highest MI prevalence compared to all other ethnic and racial women
groups1,60. Additionally, over one third of Indian American women have three or more
cardiac risk factors, and their AMI rates are now 2-fold higher than the general US
population61. At time of presentation, black and Hispanic women have more comorbidities
(DM, HTN, physical inactivity, higher lipid levels, and obesity) compared to white women,
which is thought to partially explain their higher AMI rates and inferior long-term
outcomes62,63. The same trend exists also in black women younger than 55, who suffer from
higher AMI mortality rates than white women in the same age group, even after adjusting
for socioeconomic parameters such as access to medical insurance62,63.
Finally, although women of all ethnicities are less likely to be referred to PCI and
CABG compared to men, black women are at the bottom of the totem pole when measuring
referrals to PCI and coronary angiography, even after controlling for baseline differences 64.

Pathophysiology Through the Gender Lens
The overwhelming majority of AMI cases, in both men and women, begin with an
obstructive atherosclerotic disease in an epicardial vessel, generally followed by
superimposed thrombosis. STEMI, its most dreadful form, is most often precipitated by the
disruption of a previously stable atherosclerotic plaque in an already narrowed coronary
vessel. Such a disruption exposes the vascular endothelium with its underlying
thrombogenic milieu, which in turn promotes platelet aggregation, activation of the
coagulation cascade, and ultimately thrombus formation65. The final result is an abrupt and
persistent occlusion of the affected vessel, culminating in a complete cessation of blood
flow to the associated myocardium. It has long been established that the duration of vessel
occlusion (ischemic time) is directly proportional to infarct size, a phenomenon
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characterized as “a wave front of necrosis”

66,

which is in turn associated with poorer

clinical outcomes12,67.
Current evidence supports sex-based differences in the pathophysiological
mechanisms underlying the aforementioned events68,69. These indicate that women have
different plaque characteristics, pathogenicity, burden, and distribution, as well as an
increased incidence of the more rare syndromes giving rise to STEMI such as coronary
artery spasm (CAS)70 and spontaneous coronary artery dissection (SCAD)71,72. Of note, this
pathophysiological variability is accentuated in young women, as was recently
demonstrated by the VIRGO trial, where 1 out of 8 women with AMI did not fit current
classification schemes58. Still, gender differences in the pathophysiology and progression of
CHD (mainly atherosclerosis) remain elusive, and require additional research before they
can be translated into clinical practice.

Hormone-Vessel Interplay
As previously discussed, on average CHD develops ~7 years later in women than in
men. This time lag in female morbidity and mortality was first demonstrated in the
Framingham Population44, and was punctuated by the age of menopause, hinting at the
atheroprotective effects of endogenous estrogen53. Strengthening this hypothesis further
are evidence from the Women’s Ischemia Syndrome Evaluation (WISE) study, showing that
young women with endogenous estrogen deficiency have a sevenfold increased risk for
coronary artery disease71.
Although the exact mechanisms are not completely elucidated, estrogen was
demonstrated to inhibit smooth muscle proliferation73, and to increase nitric oxide levels
leading to vasodilation74,75. Decline in the levels of estrogen at menopause was shown to
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promote endothelial dysfunction and vascular lipid deposition, both of which serve as a
preamble

to

AMI76,77.

Interestingly,

exogenous

estrogen

supplementation

in

postmenopausal women did not exhibit any efficacy in halting the progression of
atherosclerosis or in preventing CHD. Rather, it may precipitate acute cardiovascular
events in postmenopausal women45,78. Consequently, systemic estrogen supplementation is
not recommended for either the primary or secondary prevention of CHD.

Plaque Rupture vs. Plaque Erosion
Plaque rupture/disruption is the culprit event in 76% of men and 55% of women
with lethal MI79. It occurs when the thin fibrous cap encasing a lipid-rich, centrally necrotic
atherosclerotic plaque is disrupted. This newly exposed plaque is subsequently infiltrated
by macrophages, matrix metalloproteases, and lymphocytes, whose digestive actions
expose an otherwise concealed tissue factor to the blood stream80. This interaction leads to
the activation of the coagulation cascade, and quickly culminates in the formation of an
obstructive thrombus.
Evidence suggests that although plaque rupture is responsible for the lion share of
MIs in men, plaque erosion is quite common in women, particularly of young age68, with
some studies suggesting it accounts for 27% of patients with STEMI and 31% of NSTEMI81.
In fact, the only two risk factors predicting the type of coronary vessel occlusion are female
sex and premenopausal status. This is of particular interest since MI with non-occlusive
CAD is also more prevalent in young women82,83.
Erosions are characterized by denuded endothelium covering a plaque composed of
copious proteoglycans and larger proportions of proliferating smooth muscle cells than
inflammatory cells. Studies suggest that activated macrophages close to the endothelium
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are responsible for endothelial apoptosis and disruption by proteases65. Coronary vessel
obstruction and AMI develop when thrombi form on the surface of plaque erosions, where
the dysfunctional endothelium is unable to keep the coagulation cascade in check.
Microthrombi can then embolize, a phenomenon more commonly associated with plaque
erosion than with plaque rupture, causing downstream vessel occlusion and tissue
infarction84,85.
The clinical significance of the differences between rupture and erosion has yet to
be fully explored. The gold standard imaging modality that allows for plaque
characterization is optical coherence tomography (OCT), which is rarely performed due to
limited availability and unknown clinical utility. Still, some studies suggest the possibility
that optimal treatment may differ based on plaque type. Namely, replacing the stent, the
successful workhorse in treatment of plaque rupture, with aspiration thrombectomy and
transcatheter thrombolysis for plaque erosion. Thus far, minimal data supports this
hypothesis86. Finally, the interplay between plaque type and common comorbidities such
as hypertension, DM, hypercholesterolemia, and smoking has proven inconclusive87,88.

Coronary Artery Spasm
Although considered a rare mechanism of MI, CAS is known to be associated with
stable angina and transient ST–segment elevations on ECG70,89. Common triggers include
sudden changes in autonomic activity and tone90, use of ephedrines91 and other drugs92,
and cigarette smoke93. Although data on sex differences in CAS is limited, one study showed
that, compared to men, women with CAS were older, smoked less, and had less coronary
vessel obstruction94.
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Spontaneous Coronary Artery Dissection
SCAD is an exceedingly rare cause of AMI, with a reported prevalence ranging from
0.2% to 4%95-97 of patients undergoing cardiac catheterization. Its clinical presentation and
EKG findings often mimic STEMI. Similar to other less common etiologies of MI, its
incidence is higher in women, and clinical suspicion should be particularly high in young
females presenting with ACS in the absence of typical risk factors98. Although the accurate
prevalence of SCAD is unknown, reports suggest that it is identified in 10.8% of women <50
years of age who present with ACS97. It is also associated with oral contraceptive use,
pregnancy and postpartum status, connective tissue disorders (e.g., Ehlers-Danlos
syndrome), and vasculitides (e.g., fibromuscular dysplasia)99.

Diagnosis with Gender in Mind
Symptomology and Clinical Presentation
It is well established that apart from the classical AMI presentation of crushing chest
pain and pressure typical of both sexes, women often have an atypical presentation with
less severe pain and more symptoms100. Namely, they present with atypical chest pain
patterns (e.g., burning and reproducible pain), indigestion, nausea/vomiting, dyspnea,
fatigue, flu-like symptoms and generalized anxiety101-108. In STEMI, both men and women
tend to have symptoms of chest pain. However, in women, especially at younger ages, these
symptoms are often accompanied by a vaso-vegetative state that tends to attenuate or even
mask the pain, as well as lead to less conspicuous ST-T elevations109-111.
Additionally, one qualitative study found that young women reported experiencing
subtle symptoms that would wax and wane over months prior to MI112. Yet, the fear of
being characterized as anxious precluded them from communicating their worries that

10

such symptoms could represent CHD113. Interestingly, symptoms of ACS (especially classic)
are an independent MI predictor in women, even with healthy appearing coronaries69,114.
For example, referred shoulder pain, when present, is 2-fold more likely to predict ACS in
women than in men115.
For women to act on atypical CHD and MI symptoms they must be aware of their
significance, quality, and urgency. Tragically, a national survey of 1000 women conducted
in 2000, meant to assess knowledge, awareness, and perception of heart disease,
discovered a profound lack of awareness of gender-specific MI warning signals116. Whereas
67% of the women could recognize “classic” signals of MI (e.g., chest pain and tightness,
arm pain), only 10% had knowledge of the symptoms common in women (e.g., nausea,
indigestion, fatigue). Worse, 7% of the women could not provide any answer. The survey
also uncovered an even more worrisome statistic: only 18% of women learned about MI
symptoms from their own physician (18%), and although 90% reported feeling
comfortable discussing CHD prevention with their provider, 70% never did.
These sex-based differences in presentation and awareness contribute to missed or
delayed diagnoses, decreased rates of timely reperfusion, and subsequent worse outcomes
in women in general, and young women in particular117,118.

Diagnostic Armamentarium
The seemingly favorable pathologic profile in women of all ages—less obstructive
CAD (particularly triple vessel and left main disease)—results in a decreased diagnostic
accuracy, namely an increased false-positive rate with most diagnostic tests. In addition,
the lesser extent of obstructive disease on angiography combined with similar or worse
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prognosis than men renders noninvasive diagnostic methods the fulcrum of CHD and AMI
workup in women.
Over the past two decades, the use of myocardial revascularization procedures for
the treatment of diagnosed AMI, particularly STEMI, in developed countries has finally
become standardized, and essentially gender neutral119-121. As previously discussed, in
women the proper implementation of such therapeutic interventions relies heavily on the
accuracy of noninvasive tests. When such tests are abnormal, women are now more likely
to be referred to PCI than ever before119,122. Yet, the underrepresentation of women in
studies of noninvasive testing prevents an optimal evidence-based approach to clinical
decision-making123,124. These data suggest that a gender-based recalibration of common
noninvasive tests is essential.
Electrocardiogram
Current evidence suggests that the most cost-effective diagnostic approach to the
evaluation of chest pain in women is sequential testing119,125. For both practical and clinical
reasons electrocardiogram (ECG) is often the first step. In the National Hospital
Ambulatory Medical Care Survey, conducted by the CDC, younger women (<55 years)
presenting to the emergency room with chest pain were less likely to undergo ECG than
younger white men126. This trend was not detected for older patients. Guidelines issued by
the American College of Cardiology (ACC) require that, independent of gender or age, all ED
comers with chest pain should undergo a rapid electrocardiographic evaluation to rule out
AMI. Extra attention should be given to young women, whose ST-T changes tend to be less
obvious111.
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Biochemical Markers
The use of cardiac troponin assays has become a part and parcel of the universal
definition of AMI, with an increase above the upper reference limit being diagnostic of MI in
patients with signs and symptoms of myocardial ischemia127. The universal definition set
the upper reference limit as the 99th percentile of a normal reference population,
consisting mostly of male subjects. In recent years, both the accuracy of common troponin
assays and the reference limit were shown to be suboptimal128.
Recently, new high-sensitivity troponin assays have shown promise not only in
improving the diagnosis of myocardial infarction129 and leading to reductions in post-MI
deaths130,131, but also in uncovering important sex differences, with the upper reference
limit being two-fold higher in men than in women132. Recent studies demonstrated that the
use of high sensitivity troponin assay in conjunction with sex-specific diagnostic thresholds
doubled the diagnosis of MI in women (13% to 23% and 11% to 22%), with a negligible
effect in men (23% to 24% and 19% to 21%)130,133. These data may prove particularly
important not only for the traditional exclusion of NSTEMI, but also for young women or
diabetic women with STEMI, whose ECG can be deceivingly normal despite imminent
catastrophe.
Stress/Exercise Testing
Ideally, stress testing should not have any role in the diagnosis of STEMI. However,
its use or misuse has serious implications on prevention, risk stratification, resolution, and
treatment.
Exercise ECG is less sensitive in women due to the lower prevalence of
atherosclerotic obstruction. Moreover, many women do not have the exercise capacity to
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attain the necessary intensity that maximizes diagnostic value. Consequently, the
sensitivity and specificity of exercise ECG in women are 61% and 70% respectively, as
compared to 68% and 77% in men134. Furthermore, the rate of false positive ST-segment
changes in women has been quoted anywhere from 5- to 20-fold higher compared with
men. To improve the accuracy of exercise testing in women, the ACC Task Force on
Exercise Testing recommends myocardial perfusion imaging or stress echocardiography as
better initial choices135. The accuracy of exercise myocardial perfusion imaging for the
diagnosis of CHD does not differ between women and men, with a sensitivity and specificity
>80% and >70%, respectively134. Exercise echocardiography was shown to outperform
both exercise ECG and exercise radionuclide scans in identifying CHD in women135, with the
major limitation being the ability to capture adequate sonographic windows. Compared
with exercise ECG, stress echocardiography has shown superior average sensitivity (84%)
and specificity (76%)119,136,137.

Management of ST-Elevation Myocardial Infarction
At the core of the successful revolution in STEMI care and outcomes that has swept
across most of the developed world over the past two decades is the translation of clinical
and basic research into guidelines, and their implementation and optimization in the form
of STEMI systems of care. That is, the design of a streamlined algorithm with assembly line
efficiency that hinges on several key principles: patient education (e.g., quick symptom
recognition and early contact with emergency medical services [EMS]); synchronization of
destination and treatment protocols for EMS personnel (e.g., merging the fastest route
philosophy with choosing the most capable hospital); effective protocols in emergency
departments to minimize door-to-reperfusion times (e.g., rapid assessment and activation
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of the cath lab); and finally prompt deployment of the most suitable reperfusion strategy
(e.g., D2B < 90min or thrombolysis < 30min) by a capable team9,10,14,138. These are also
collectively known as the STEMI chain of survival.
The next breakthrough in STEMI care, both in developed countries and most
certainly in lower-income countries, will most likely result from further implementation
and optimization of the assembly line to shorten total ischemic time (i.e., Time to
Treatment), and tailoring reperfusion strategies to specific patient populations139-141. As in
the realms of epidemiology, pathophysiology, and diagnosis, previously discussed, sex
differences also exist in the management of STEMI. These manifest both in metrics
evaluating the efficiency of the chain of survival, as well as in clinical response to the
different reperfusion strategies.
Time-to-Treatment
Given the importance of time to reperfusion67, the medical community has set
benchmarks for STEMI systems of care10. These include limiting ischemic time < 120
minutes, and maintaining are a door-to-needle (i.e., fibrinolysis) time <= 30 minutes and a
D2B time (i.e., PPCI) of <= 90 minutes10,18,142.
Delay in seeking medical attention after the onset of STEMI symptom is a problem
afflicting both men and women. Many studies have found that the median delay time in
seeking care ranges from 2 to 5 hours143, with an overall range of up to 53.7 hours144,145.
Although some data indicates that upon recognition of cardiovascular symptoms women
tend to call 9-1-1 more often than men146, multiple studies have found that women with
AMI tend to present to medical care later than men143,147,148. One study found that while the
median symptom-to-presentation time was 15.6 hours for men, it was 53.7 hours in
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women149 (both significantly exceeding guidelines of total ischemic time <120 min). Most
recently, the VIRGO trial showed that compared to young man, young women who were
diagnosed with STEMI and received reperfusion therapy, were more likely to present >6
hours after symptom onset (35% versus 23%; P=0.002)26.
Many factors were found to be associated with delay in seeking treatment for STEMI
symptoms. These include barriers to self-care, inadequate understanding of health risk, and
incorrect attribution of symptoms113,150. In the US, older age, being black or Hispanic, lack
of education, and lower socioeconomic status were also associated with delays in seeking
medical attention143. Lastly, having a history of specific comorbidities (e.g., DM,
hypertension and dyslipidemia), living alone, confiding in a family member instead of a
physician, and fear and feelings of shame were all associated with delays in pursuing
treatment options after the onset of symptom143.
Although data from various regions of the world, particularly lower-income
countries, is often lacking, it stands to reason that in addition to region specific obstacles
for women24 (e.g., cultural and societal differences, poor infrastructure, or patriarchal
family dynamics), the factors described above paly a large role in perpetuating this delay in
women4.
Thrombolysis
Thrombolytic agents, most commonly tissue plasminogen activator (t-PA) and its
synthetic variants, work by dissolving occlusive thrombi, thus recanalizing culprit vessels,
restoring coronary blood flow, and minimizing infarct size65. In STEMI patients, timely
intravenous fibrinolysis (door-to-needle <30 minutes) improves survival over both the
short and long term10,151,152, an effect that is independent of sex153. The most dramatic
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mortality benefits are seen when fibrinolysis is initiated <120 minutes after symptom
onset154. Consequently, the ACC/AHA STEMI guidelines recommend thrombolytic therapy
for both men and women with no contraindications, who cannot be transported to PCIcapable hospitals or have an anticipated delay in symptom-to-PCI time of >120 minutes155.
Compared to men, women who receive thrombolytic therapy have higher morbidity
and mortality rates59,109,143,156. These may be related to higher rates of reinfarction, shock,
heart failure, stroke, and bleeding156-158. The elevated risk of reinfarction was reduced in
women when enoxaparin was used in conjunction with thrombolytics, however at the
unintended cost of increased bleeding risk159. The Global Utilization of Streptokinase and
Tissue Plasminogen Activator for Occluded Coronary Arteries 1 (GUSTO-1) trial found that
while 90-minute vessel patency rates and global ejection fraction results were similar for
men and women, the thrombolysis-associated bleeding risk was 1.43-fold higher in
women160.
Reported mortality benefits of thrombolysis vary considerably, based on the patient
population and the use of adjunctive therapies. For example, in women, who tend to
present with STEMI at significantly older ages, the effect of age on successful thrombolysis
is amplified. Data shows that older patients with STEMI have the following barriers to
timely administration of thrombolytic therapy: prolonged delay in seeking medical care,
lower incidence of classic ischemic symptoms and higher incidence of atypical symptoms,
more comorbidities, presence of relative contraindications, and non-diagnostic ECGs65,161.
The risks and complications associated with thrombolysis together with data on the
superiority and widespread implementation of PCI have significantly decreased the use of
fibrinolysis in the majority of developed nations. Nevertheless, in many regions of the
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developing world, where barriers such as infrastructure, funding, and training prevent the
establishment of an efficient PCI-capable system, thrombolysis continue to be mainstay
therapy. In these regions, understanding the interplay between thrombolysis and sex
remains relevant.
Primary Percutaneous Coronary Intervention
Today, PCI is an umbrella term for a wide array of procedures: balloons, stents,
adjunct devices, thrombectomy, and pharmacologic agent delivery, all necessary for a safe
and effective navigation of a complex coronary geography65. When performed rapidly and
in an experienced center, primary PCI was proven superior to intravenous thrombolytic
therapy for both men and women with STEMI162,163. Consequently, the use of primary PCI
has expanded dramatically over the past two decades, and in the absence of complex multivessel CAD, has become the modality of choice for emergent revascularization in the United
States and most of the developed world10. ACC/AHA and ESC guidelines for STEMI care
define timely reperfusion with PCI as hospital D2B time <90 minutes for patients who selftransport and EMS-to-balloon time <90 minutes for patients arriving by ambulance. Still,
controversy exists as to whether PCI remains the superior modality in cases of substantial
delay; as in places where 24-hour primary PCI is unavailable10.
In women, primary PCI was found to have a significant mortality benefit as
compared to thrombolysis, which, as previously discussed, has a very high complication
rate. In the GUSTO II-B trial primary PCI prevented 56 deaths per 1000 treated patients in
women as compared to 42 deaths in men164. Despite almost eliminating the risk of
intracranial bleeding associated with thrombolytic therapy165, women undergoing PCI still
had higher rates of vascular complications requiring transfusions166,167. Use of early-

18

generation stents for AMI was initially associated with higher mortality rates in women168,
however, later studies found that compared to angioplasty alone, bare-metal stenting was
associated with reduced major adverse cardiac events (MACE) and reinfarction rates166. A
recent patient-level pooled analysis of randomized trials in women undergoing coronary
stenting found that compared to bare metal stents and early generation drug eluting stents
(DES), women receiving new-generation DES had lower rates of death, MI, and target
vessel revascularization169.
Finally, in an analysis of 22 trials randomizing 6,763 STEMI patients to either
primary PCI or thrombolysis, women had a lower 30-day mortality with PCI, irrespective of
time to reperfusion170. Mortality rates were 7.7% versus 9.6% for women presenting
within the first 2 hours of symptom onset, and 8.5% versus 14.4% when presenting after a
delay >2 hours. Notably, the highest mortality was observed in women with a delayed
presentation who were treated with thrombolytic therapy.
Coronary Artery Bypass Graft
Emergency CABG as a treatment modality for STEMI is exceedingly rare. Even in
patients with triple-vessel disease, it usually reserved to the post PCI period, after initial
vessel patency had already been achieved. Several outcomes studies, with data stratified by
sex, show, that post CABG, women tend to have higher in-hospital mortality rates. Although
women presenting for CABG were on average older and sicker, adjustments for such
baseline characteristics only attenuated, but did not eliminate this outcome
discrepancy171,172.
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Prognostic Factors and Adverse Outcomes
Although several risk prediction models for adverse events post AMI, such as Global
Registry of Acute Coronary Events (GRACE) and Thrombolysis in Myocardial Infarction
(TIMI), are often used in patients with ACS, women account for only one third of the
population studied to create these models. Consequently, their ability to accurately predict
and stratify risk in women is questionable173,174. A recent study that used prognostic values
such as left ventricular ejection fraction and certain ECG measures was able to stratify 5year mortality risk in both men and women, but the prediction strength and accuracy
varied between the sexes. For example, lack of sinus rhythm was associated with a 2–fold
increased hazard ratio in women than in men. The study concluded that sex-specific
models provided more accurate risk stratification than their traditional, sex-neutral
counterparts175.
Creating sex-specific models requires taking into account the previously described
variations in presentation and baseline characteristics, traditional coronary risk factors,
and psychosocial effects. For example, women with STEMI that present without chest pain
have an increased risk of in-hospital mortality regardless of age group117,176. Such lack of
pain on presentation is independently associated with increased mortality in women more
so than in men117. Additionally, DM nearly doubles the long-term mortality risk in women
after MI, an effect that is, once again, more pronounced in women. As previously discussed,
other coronary risk factors such as hypertension, smoking, and obesity have high
prevalence in women admitted with AMI, especially in developing countries. A study that
followed 19 centers indicated that while among all AMI patients over two thirds had ≥2
risk factors and over one third had ≥3 risk factors, black women had the highest amount of
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risk factors among the different sub-populations. Two thirds of older and half of younger
black women had ≥3 risk factors62.
Finally, there is increasing evidence that negative psychosocial factors, particularly
depression, are associated with poorer ACS outcomes177. In patients with ischemic heart
disease mental stress-induced ischemia increases mortality and recurrence of cardiac
events by 50%178. These data are especially relevant when assessing prognosis in women,
who bear a higher burden of psychosocial risk factors compared to men at all age
groups179,180. Approximately one fifth of post MI patients suffer from depression, and
depression rates in women with MI are two fold higher than in men177. Half of women with
AMI younger than fifty and over 40% of women 50-60 years old suffer from clinical
depression180. This increases their risk of death or additional MACE by almost 3-fold181-183.
Furthermore, social support was found to be a positive prognostic factors in post MI
women, and is associated with better psychological function, higher quality of life, and
reduced rates of depression one-year post MI184. The significance of psychosocial stress in
women with AMI was also demonstrated in experimental studies where emotional stress
was induced in women with prior ischemic heart disease or MI, and was shown to cause
myocardial ischemia. These studies found higher rates of stress induced myocardial
ischemia in women than in men185.
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Statement of Purpose

Over the past decade, the United States and most European countries have seen, for
the first time, a significant reduction in ACS mortality in women. These encouraging
trends are, in part, the result of growing awareness to long-lasting sex disparities,
increased attention to specific cardiovascular risk factors and pathophysiology in women,
and the implementation of evidence-based guidelines and systems of care for AMI
patients as a whole (i.e., SFL and Mission: Lifeline).
Nevertheless, ACS in general, and STEMI in particular, remain a leading cause of
morbidity and mortality afflicting millions of women both in the US and worldwide.
While the reasons for the increased incidence of AMI among women are numerous and
may be related the increased prevalence of comorbidities, age, race, ethnicity, and
socioeconomic trends one thing seems clear—women are late to reap the full benefits of
the STEMI revolution that has swept most of the developed world over the past two
decades. What is more, women in developing countries and underprivileged women in
more developed nations bear the brunt of this persistent gender gap in STEMI care and
outcomes.
With the constant trickle of sporadic data on sex-based disparities in STEMI care and
outcomes, the once considered mythical gender-gap has been receiving increasing
amounts of attention. Nevertheless, to date, a comprehensive, global analysis of genderbased outcome has never been performed. We believe that the first step in addressing any
such problem is evaluating the quality of existing data (e.g., amount, connectedness),
gauging the magnitude of the problems, and taking an initial stab at unveiling regional
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and global trends. This meta-analysis aims to provide partial answers to these questions,
as well as to invigorate others to collaborate and tackle these same topics. Every
conversation needs an intermittent stimulus to remain relevant; hopefully our data will
serve as a spark.
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Methods
Data Sources and Search Strategy
A systematic literature search in PubMed of all studies published from 2000 to
present was performed according to the Preferred Reporting Items for Systematic Reviews
as detailed in the checklist in Table 3. Two independent reviewers (HL and IH) performed
the search, selected the studies and validated the selection process as detailed in Figure 1.
Using the search terms “sex”, “gender” and “STEMI,” 613 studies were initially identified by
one of the co-primary authors. Each study written in English was manually reviewed, and
only studies reporting sex-based STEMI mortality outcomes were included. After the
exclusion of 505 studies based on these initial search criteria, 108 studies remained. Of
these, 17 studies were excluded because they spanned data preceding the year 2000. An
additional 10 studies were excluded because they were reviews or meta-analyses and did
not include primary data, 5 studies were excluded because the sex-based mortality data
were reported as sub-stratified or fragmented data, and 1 study was excluded due to the
small sample size of included women (below 50). These selection criteria yielded 75
studies for inclusion in the meta-analysis (Table 4).

The second co-primary author

replicated the search in a blinded manner to validate the search criteria and demonstrate
reproducibility.
Endpoint Selection
The primary clinical endpoints were in-hospital and 12-month mortality; other time
points included 30 days and 6 months. In addition, as secondary endpoints, we evaluated
sex differences in baseline characteristics and D2B times.
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Statistical Analysis
Meta-analyses were conducted using random effects models. Heterogeneity was
assessed via Cochran’s Q statistic. Odds ratios and 95% confidence intervals from the
random effects models are displayed grouped by region and overall. All available data was
used at each reported time point, there was no imputation of missing data. Bias was
assessed via visual assessment of funnel plots of the effect differences versus study size.
Sensitivity analyses were conducted by excluding studies under various conditions
including (1) studies in which all patients underwent reperfusion therapy, and (2) studies
that included only patients presenting within a pre-specified time-frame following onset of
symptoms. All analyses were performed using NCSS 2007 186.
Meta regressions were conducted using SAS software version 9.4 (SAS Institute Inc.,
Cary, NC, USA). Models to examine the impact of moderator variables on study effect sizes
for in hospital and 12-month mortality were run adjusting for the normalized mean age
(mean/standard deviation), the percent of men and women with hypertension and the
percent of men and women with diabetes, within each study.
Contributions
Data collection, refinement, and selection were done in collaboration with Dr.
HyonJae Lee. I devised the initial searching algorithm and data collection methodology, and
these were further improved and optimized by Dr. Lee. Dr. Lee and I also collaborated on
preparing and “cleaning” the data for statistical analysis. I performed preliminary statistical
analysis (on a smaller scale study as a proof of concept). Helen Parise, a statistician
working with Dr. Lansky and the Yale Cardiovascular Research Group, performed the
comprehensive statistical analysis presented in this work.
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Results
Of the original 613 citations identified, a total of 75 studies qualified for inclusion in
the meta-analysis (Figure 1). There were a total of 731,990 patients comprised of 233,310
(32%) women and 499,697 (68%) men (Table 4, and Figure References section). The
studies represent 29 countries, grouped into 6 geographic regions: North America, Europe,
Eastern Europe, Nordic Countries, Middle East/Israel, Australasia, and mixed multiregional countries (Table 5). Of the 75 included studies, 31 studies included only patients
undergoing reperfusion therapy (N=189,791; 28.7% men and 20% women, p<0.001) and
18 studies excluded patients presenting after a pre-specified period of time (range 12-72
hours) following onset of symptoms (Table 6). One U.S. study included only patients
presenting with STEMI in cardiogenic shock and 1 study from the Netherlands excluded
patients with cardiogenic shock. One study included only patients with diabetes, 2 studies
excluded patients with chronic kidney disease, 1 study excluded patients with
contraindication to anticoagulation. Three studies included only patients with anterior
STEMI, 3 studies included only patients with first-time STEMI, 1 study included only
patients with multi-vessel disease. Overall, women presenting with STEMI were older than
men and had a higher prevalence of hypertension and diabetes, but were less likely to be
active smokers or have a history of prior myocardial infarction (MI) (Table 1).
Primary Endpoints
Primary PCI was reported in 23.2% of men and 16.3% of women, (p<0.001). Overall
unadjusted in-hospital mortality was 2-fold higher in women compared to men and
consistently higher in all regions evaluated (OR 2.09; 95% CI 1.91-2.28; p<0.0001) (Figure
2). Overall unadjusted mortality rates for women were at least 70% higher at all follow-up
time points including 1-year (OR 1.76; 95% CI 1.63-1.90; p<0.0001) (Figure 3), 6-month
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(OR 1.72; 95% CI 1.38-2.14; p<0.0001), and 30-day (OR 1.74; 95% CI 1.65-1.84; p<0.0001)
(Figure 4). The greatest sex-disparity in mortality was reported in the Middle East, where
women had a 10-fold higher in-hospital mortality and a greater than 2 fold higher mortality
at 30 days and 1 year. The highest absolute in-hospital mortality rates for women were
reported in North America due to the inclusion of a large study of cardiogenic shock, and
the highest absolute out-of-hospital mortality at 30-day, 6-month, and 1-year follow-up
were reported in Eastern Europe. Review of the funnel plots indicated minimal publication
bias (Figure 6).
Sub-analysis excluding studies in which all patients underwent reperfusion therapy
(32 studies, N=189,791) did not significantly change overall relative mortality outcomes inhospital (2.12 OR, 95%CI 1.90-2.37; p<0.0001), at 30 days (1.80 OR, 95%CI 1.61-2.02;
p<0.0001), or at 1 year (1.87 OR, 95%CI 1.69-2.07; p<0.0001). Sub-analysis excluding
studies that included only patients presenting within a pre-specified time-frame following
onset of symptoms also did not significantly change overall relative mortality outcomes inhospital (2.09 OR, 95%CI 1.90-2.30; p<0.0001), at 30 days (1.78 OR, 95%, CI 1.56-2.03;
p<0.0001), or at 1 year (1.80 OR, 95%CI 1.63-1.98; p<0.0001).
Adjusting for age alone (N=233,039) in the meta-regression did not affect the
observed differences in mortality between men and women at any time point (OR 1.92;
p=0.0002 for in-hospital mortality, and OR 1.71; p=0.014 for 12 month mortality). After
adjusting for age and differences in hypertension and diabetes (the two most frequently
reported comorbidities; N=164,815), the difference in outcomes both in-hospital and at 12
months though still favoring outcomes in men, were no longer statistically significant, (OR
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1.71; p=0.34 for in-hospital mortality and OR 1.51; p=0.51 for 12-month mortality) (Table
2).
Secondary Endpoints
As previously described, Primary PCI was reported in only 16.3% of women,
limiting our ability to accurately and comprehensively assess D2B times. Furthermore,
there exists a rather large region-based variability in reporting practices, as well as in
common types of interventions (i.e., PPCI vs. thrombolysis). Nevertheless, D2B time for
women, compared to men, was longer in all countries with a mean delay of 5.3 minutes
(range: 0-10; p<0.0001) (Figure 5). Interestingly, the largest delays were observed in
Australasia (9.94 min, 95%CI -1.64-21.52), Europe (7.11 min, 95%CI 3.41-10.80), North
America (6.52 min, 95%CI 1.79-11.25), and in the Mixed group (4.0 min, 95%CI 0.50-7.50).
The large delays in North America and Europe should be interpreted with the
understanding that these regions collect and report the most robust data both
quantitatively and qualitatively, thus allowing for a more meaningful statistical analysis
with significantly less heterogeneity. This discrepancy between observed delays in D2B
times and clinical outcomes is highlighted when looking at data from the Middle East.
There, we detect a minimal delay in D2B time (5 min, 95% -3.65-3.75), which is not
statistically significant, but at the same time we observe the largest sex-disparity in
mortality (10-fold higher in-hospital mortality and a >2 fold higher mortality at both 30
days and 1 year).
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Discussion
This systematic meta-analysis represents a comprehensive contemporary study that
examines sex-based STEMI outcomes on a global scale. When evaluating the data globally
(Table 2), this work demonstrates that, compared to men, women have more coronary risk
factors, undergo less reperfusion therapy, and experience a mortality excess of more than
two-fold in-hospital and more than 70% at 12-month following hospitalization for AMI.
A region-by-region analysis shows consistent excess in women’s mortality
compared to men (Fig. 2, 3). This discrepancy did not spare the U.S. or Europe, where
STEMI systems of care are already well established. Overall delays in reported D2B times
for women, while statistically significant, were relatively small (Fig. 5). Additionally, the
largest D2B delays, detected in the most developed regions (e.g., North America and
Western Europe), merit a closer look. A careful observation reveals a rather consistent
discordance between delays in D2B times and mortality rates. Regions like Eastern Europe
and the Middle East exhibit the smallest delays in D2B times (not statistically significant),
while at the same time these same regions suffer from the highest in-hospital and 1-year
mortality rates. This trend is reversed when observing the more developed regions (e.g.,
North America), where much longer delays in D2B times are recorded, but mortality rates
are much lower (Fig 2, 3). We believe that this is the result of a lower signal-to-noise ratio
in developing nations, which results from the scarcity of standardized registries, lack of
clinical trials, more homogeneous patient populations, heterogeneity of treatment
strategies, and less resources to implement efficient PCI networks.
Consequently, delays in D2B times are unlikely to be the principal driver of the
mortality difference. In fact, among Medicare patients suffering AMI (STEMI and NSTEMI),
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Guideline Determined Medical Therapy (GDMT) explains only 7% of the variation in
outcomes. This not only highlights both the magnitude and multifactorial nature of the
problem, but also implicates other underlying causes. Specifically, our data suggest that
despite improved systems of care, women’s higher mortality persists, and is probably in
large part the result of upstream modifiable risk factors.
Indeed, our study confirms differences in risk profile previously reported in other
studies, with women typically presenting at an older age and with more comorbidities than
men187-190. Moreover, previous data suggest that the sex discrepancy in comorbidity
burden is even more pronounced in developing, lower-income countries3,20,24. The
significance of modifiable risk factors on mortality is emphasized when our analysis is
adjusted for differences in age, hypertension, and diabetes (the most prevalent and
consistently reported covariates). Such an adjustment eliminates both the in-hospital and
12-month disparity in mortality (Table 2).
Our findings are consistent with published data suggesting that, at least in the US,
the higher STEMI mortality rate in women is largely due to comorbidities and the
prevalence of risk factors rather than treatment discrepancies191,192. This meta-analysis
suggests that risk factors may be pivotal upstream contributors to the sex mortality gap in
developed countries—both acutely and at 1 year. It is important to note that although some
data exist to suggest that women face additional upstream challenges in access to care, they
are limited in scope, accuracy, and depth particularly. This is especially true in many parts
of the developing world, where systematic, standardized data collection is frequently not
practiced.
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As previously discussed, women’s underrepresentation in cardiovascular clinical
trials (~20% of enrolled patients) and in longitudinal studies and registries (~40% of
enrolled patients) is of historic magnitude. To add insult to injury, even clinical trials that
were conducted with equal representation, often were not sub-stratified by sex. The effect
of this marginalization echoes even louder in the era of evidence-based medicine, as it
limits the quantity and quality of sex-specific data available to both providers and
patients42.
Consequently, this study, which only incorporates data from regions and hospitals
with sufficient resources to maintain registries, is representative of a best-case scenario,
and does not adequately capture many of the challenges women face in accessing care. This
critical information gap masks upstream barriers to care, which often affect vulnerable
populations, including women, more profoundly. These barriers may include lack of
awareness and recognition of STEMI symptoms28, variations in threshold for seeking
medical attention, insufficient management of modifiable risk factors, region-specific
transportation, and financial, social, religious and cultural impediments to care 11,20.
This global analysis reveals the latitude and magnitude of widely recognized sex
disparities in STEMI care and outcomes. However, its most powerful function is exposing
our global ignorance of the epidemiological, clinical, and social barriers to high-quality
STEMI care for women. The major impediment to the improvement of STEMI care and
outcomes for women is the lack of comprehensive and accurate data.
Closing this information gap requires a rigorous reevaluation of sex-specific
differences and their clinical implications. This long overdue task should consist of a twopronged approach: 1. Expanding basic science and translational research to further
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characterize differences in coronary pathophysiology, optimize diagnostic modalities with
gender in mind, and evaluate pharmacotherapies and invasive treatment strategies in light
of new data at the subpopulation level (e.g., young vs. older women, women of certain races
and income levels etc.). An example of one such practical step would be changing the
practice of excluding elderly patients from clinical trials, a “tradition” that works to the
detriment of women, whose CHD develops predominantly at older ages. 2. Implementing
public health initiatives to tackle economic, political, regulatory, cultural, environmental,
health systems, and policy challenges both locally and globally193. A desperately needed
first step in improving treatment availability and outcomes for women with STEMI is the
creation of large, uniform, global registries with reliable data on demographic risk factors,
use of reperfusion, and patient outcomes.
As we enter the age of personalized medicine, attention to sex-specific
characteristics and disparities will become inescapable. It will improve prevention,
recognition, treatment, and outcomes for women with STEMI. The remaining questions are
what will the rate of change be? And, how do we make sure developing nations do not stay
behind for yet another two decades? We cannot answer these questions when in the US, the
hub of innovation and cutting edge medicine, women constituted ~1/3 of all participants in
the 78 cardiovascular device trials between 2002 and 2007194. How can we instigate global
change, when the Food and Drug Administration does not mandate, sex-specific data in
device studies despite mounting evidence that the safety and efficacy of cardiovascular
devices vary by sex194,195? Enough said.
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Limitations
This meta-analysis is intended to be comprehensive and systematic, but inherently
has several unavoidable limitations. Most importantly, many of the studies included in this
analysis come from larger hospitals with PPCI capabilities and individual data-storage
systems, resulting in a reporting bias and likely representing a best-case scenario. Thus, it
is likely that our analysis under-estimates mortality rates and delays-to-reperfusion,
particularly when accounting for the paucity of data from more rural, resource scarce
regions. There are also limitations intrinsic to a meta-analysis, including a heterogeneity of
studies with varying inclusion and exclusion criteria, selection bias within studies that may
not be necessarily representative of a general population of patients, and the potential for
regional under-reporting. For example, the highest in-hospital absolute mortality rates
were in North America because the North American mortality data incorporates a large
study including only patients with cardiogenic shock.

Additionally, the difference in

absolute mortality rates raises concerns over systematic under-reporting of mortality
events in many regions of the world – potentially from lack of access to care and loss to
follow-up. However, an adequately powered study with the inclusion of a large number of
studies decreases the likelihood that the overall results are significantly affected by subsets
of patients. Furthermore, assessment of bias by funnel plots of the effect differences versus
study size confirms minimal variability in outcomes between studies for both in-hospital
and 12 month mortality outcomes and D2B times (Figure 5). In addition, analysis of subgroups (1. Inclusion of only patients undergoing reperfusion; 2. Inclusion of only patients
presenting within a specified time frame following symptoms) did not significantly impact
the results.
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Figure Legends
Figure 1.
Title: Search criteria and methodology for selecting included studies
Caption: A systematic literature search in PubMed of all studies published from 2000 to
present was performed using the search terms “sex”, “gender” and “STEMI.” All studies
written in English were manually reviewed, and only studies reporting sex-based STEMI
mortality outcomes were included. Studies were also excluded if they did not include
primary data or due to the small sample size. These selection criteria yielded 75 studies for
inclusion.
Figure 2.
Title: In-hospital STEMI mortality by region
Caption: In-hospital mortality was 2-fold higher in women compared to men, and
consistently higher in all regions evaluated.
Figure 3.
Title: 1 year STEMI mortality by region
Caption: 1 year mortality rates were at least 70% higher in women compared to men, and
consistently higher in all regions evaluated.
Figure 4.
Title: 30 day STEMI mortality by region
Caption: 30-day mortality rates were at least 70% higher in women compared to men, and
consistently higher in all regions, with the exception of North America.
Figure 5.
Title: Delay in door to balloon times by region
Caption: Door-to-reperfusion time for women was longer in all countries with a mean
delay of 5.3 minutes. Not all regions demonstrated statistical significance.
Figure 6.
Title: Funnel plots for study variability in mortality and D2B times
Caption: While clinical heterogeneity is present to some degree in all meta-analyses, the
large scale of this meta-analysis, the geographic variability, and the relatively large time
span require an assessment of statistical heterogeneity. Bias was assessed via visual
assessment of funnel plots of the effect differences versus study size
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Figures
Figure 1. Search criteria and methodology for selecting included studies.
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Figure 2. In-hospital STEMI mortality by region

* [34, 37, 39, 45, 47, 61, 62, 72, 73, 75]; † [28, 41, 50, 55, 56, 59, 70]; ‡ [1, 2, 4, 5, 6, 8, 11, 12, 13, 14, 16, 18, 21, 27, 30, 33, 36, 46, 52, 54,
65, 66]; § [20] ll [30, 69]; # [19, 29, 32, 57, 58]; ** [23, 24, 26, 48, 51, 74] (Reference List in Appendix)

Figure 3. 1 year STEMI mortality by region

* [10, 71]; † [44, 50, 53, 55, 56, 59]; ‡ [1, 5, 18, 27, 54]; § [42, 67]; ll [22, 32, 57, 58]; ** [2, 60] (Reference List in Appendix)
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Figure 4. 30-day STEMI mortality by region

* [9, 10, 34, 35, 49, 71, 73] † [25, 43, 44, 50, 53, 55, 56, 59] ‡ [11, 63] § [31, 42] ll [64, 69] # [7, 22, 40] ** [51] (Reference List in Appendix)

Figure 5. Delay in door to balloon times by region

* [9, 10, 34, 38, 39, 47, 62, 71] † [25, 53, 55] ‡ [4, 6, 8, 11, 33, 62, 63, 65] § [31, 42, 67] ll [69] # [15, 19, 40, 68] ** [2, 23, 51] (Reference
List in Appendix)
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Figure 6. Funnel plots for study variability in mortality (a,b) and D2B time (c)

(a) In-Hospital Mortality

(b) 12-M Mortality

(c) Door-to-Balloon Time
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Tables
Table 1. Demographics of patients included in the meta- analysis

(a)

MI = Myocardial Infarction; * Percentages reflect the studies that report the specified clinical characteristic

Table 2. Odds ratio of death adjusted to clinical variables Give N for each group
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(a)

HTN = Hypertension; (b) DM = Diabetes; (c) OR = Odds Ratio; * Adjusted for age, HTN and DM simultaneously.
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Table 3. MOOSE Checklist
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Table 4. Characteristics of studies included for analysis

* See Figure References section for citation list of included studies
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Table 5. Studies by geographic region

(a) Australasia = Australia and Asia * See Figure References section for citation list of included studies

Table 6. Significant Inclusion and Exclusion Criteria of Included Studies

(b) STEMI = ST-elevation Myocardial Infarction * See Figure References section for citation list of all studies
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